Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Reproductive Biology and Endocrinology
Published in: Reproductive Biology and Endocrinology 1/2016

Open Access 01-12-2016 | Review

Obstetric and offspring risks of women’s morbid conditions linked to prior anticancer treatments

Authors: Juan J. Tarín, Miguel A. García-Pérez, Antonio Cano

Published in: Reproductive Biology and Endocrinology | Issue 1/2016

Login to get access

Abstract

Background

Literature shows the effects of type of cancer and/or anticancer treatment on live birth percentages and/or pregnancy and neonatal complications in female cancer survivors. However, studies analyzing the obstetric and offspring risks of the morbid conditions associated with previous anti-cancer treatments are missing. The present review aims to uncover these risks.

Methods

A literature search based on publications up to March 2016 identified by PubMed and references cited in relevant articles.

Results

The morbid conditions associated with prior anticancer treatments including chemotherapy, radiotherapy, surgery, and/or hematopoietic stem-cell transplant may induce not only obstetric and neonatal complications but also long-term effects on offspring. Whereas some risks are predominantly evidenced in untreated women others are observed in both treated and untreated women. These risks may be superimposed on those induced by the current women’s trend in Western societies to postpone maternity.

Conclusions

Medical professionals should be aware and inform female cancer survivors wishing to have a child not only of the short- and long-term risks to themselves and their prospective offspring of previous anticancer treatments, fertility-preservation technologies, and pregnancy itself, but also of those risks linked to the morbid conditions induced by prior anticancer treatments. Once female cancer survivors wishing to have a child have been properly informed about the risks of reproduction, they will be best placed to make decisions of whether or not to have a biological or donor-conceived child. In addition, when medical professionals be aware of these risks, they will be also best placed to provide appropriate treatments before/during pregnancy in order to prevent or alleviate the impact of these morbid conditions on maternal and offspring health.
Literature
1.
Tschudin S, Bitzer J. Psychological aspects of fertility preservation in men and women affected by cancer and other life-threatening diseases. Hum Reprod Update. 2009;15:587–97.CrossRefPubMed
2.
3.
Travis LB, Ng AK, Allan JM, Pui CH, Kennedy AR, Xu XG, et al. Second malignant neoplasms and cardiovascular disease following radiotherapy. Health Phys. 2014;106:229–46.CrossRefPubMed
4.
Knopman JM, Papadopoulos EB, Grifo JA, Fino ME, Noyes N. Surviving childhood and reproductive-age malignancy: effects on fertility and future parenthood. Lancet Oncol. 2010;11:490–98.CrossRefPubMed
5.
Canada AL, Schover LR. The psychosocial impact of interrupted childbearing in long-term female cancer survivors. Psychooncology. 2012;21:134–43.CrossRefPubMed
6.
Armuand GM, Wettergren L, Rodriguez-Wallberg KA, Lampic C. Women more vulnerable than men when facing risk for treatment-induced infertility: a qualitative study of young adults newly diagnosed with cancer. Acta Oncol. 2015;54:243–52.CrossRefPubMed
7.
West ER, Zelinski MB, Kondapalli LA, Gracia C, Chang J, Coutifaris C, et al. Preserving female fertility following cancer treatment: current options and future possibilities. Pediatr Blood Cancer. 2009;53:289–95.CrossRefPubMedPubMedCentral
8.
Dittrich R, Maltaris T, Hoffmann I, Oppelt PG, Beckmann MW, Mueller A. Fertility preservation in cancer patients. Minerva Ginecol. 2010;62:63–80.PubMed
9.
Smyth C, Robertson I, Higgins L, Memeh K, O’Leary M, Keane M, et al. Fertility preservation in young females with non-gynaecologic malignancy: an emerging speciality. Ir J Med Sci. 2014;183:33–8.CrossRefPubMed
10.
Lambertini M, Ginsburg ES, Partridge AH. Update on fertility preservation in young women undergoing breast cancer and ovarian cancer therapy. Curr Opin Obstet Gynecol. 2015;27:98–107.CrossRefPubMed
11.
Practice Committee of American Society for Reproductive Medicine. Ovarian tissue cryopreservation: a committee opinion. Fertil Steril. 2014;101:1237–43.CrossRef
12.
Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology. In vitro maturation: a committee opinion. Fertil Steril. 2013;99:663–6.CrossRef
13.
Practice Committee of the American Society for Reproductive Medicine. Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion. Fertil Steril. 2013;100:1214–23.CrossRef
14.
Practice Committee of the American Society for Reproductive Medicine. Definition of experimental procedures: a committee opinion. Fertil Steril. 2013;99:1197–8.CrossRef
15.
Ethics Committee of American Society for Reproductive Medicine. Fertility preservation and reproduction in patients facing gonadotoxic therapies: a committee opinion. Fertil Steril. 2013;100:1224–31.CrossRef
16.
Tawn EJ, Rees GS, Leith C, Winther JF, Curwen GB, Stovall M, et al. Germline minisatellite mutations in survivors of childhood and young adult cancer treated with radiation. Int J Radiat Biol. 2011;87:330–40.CrossRefPubMed
17.
Green DM, Lange JM, Peabody EM, Grigorieva NN, Peterson SM, Kalapurakal JA, et al. Pregnancy outcome after treatment for Wilms tumor: a report from the national Wilms tumor long-term follow-up study. J Clin Oncol. 2010;28:2824–30.CrossRefPubMedPubMedCentral
18.
Guo Y, Cai Q, Samuels DC, Ye F, Long J, Li CI, et al. The use of next generation sequencing technology to study the effect of radiation therapy on mitochondrial DNA mutation. Mutat Res. 2012;744:154–60.CrossRefPubMedPubMedCentral
19.
Winther JF, Olsen JH, Wu H, Shyr Y, Mulvihill JJ, Stovall M, et al. Genetic disease in the children of Danish survivors of childhood and adolescent cancer. J Clin Oncol. 2012;30:27–33.CrossRefPubMed
20.
21.
Lawrenz B, Henes M, Neunhoeffer E, Fehm T, Huebner S, Kanz L, et al. Pregnancy after successful cancer treatment: what needs to be considered? Onkologie. 2012;35:128–32.CrossRefPubMed
22.
Nakamura N, Suyama A, Noda A, Kodama Y. Radiation effects on human heredity. Annu Rev Genet. 2013;47:33–50.CrossRefPubMed
23.
Rubio C, Rodrigo L, Mercader A, Mateu E, Buendía P, Pehlivan T, et al. Impact of chromosomal abnormalities on preimplantation embryo development. Prenat Diagn. 2007;27:748–56.CrossRefPubMed
24.
Webber DM, MacLeod SL, Bamshad MJ, Shaw GM, Finnell RH, Shete SS, et al. Developments in our understanding of the genetic basis of birth defects. Birth Defects Res A Clin Mol Teratol. 2015;103:680–91.CrossRefPubMed
25.
Matthews ML, Hurst BS, Marshburn PB, Usadi RS, Papadakis MA, Sarantou T. Cancer, fertility preservation, and future pregnancy: a comprehensive review. Obstet Gynecol Int. 2012;2012:953937.CrossRefPubMedPubMedCentral
26.
Andersen SL, Olsen J, Laurberg P. Foetal programming by maternal thyroid disease. Clin Endocrinol (Oxf). 2015;83:751–8.CrossRef
27.
Rossi AM, Vilska S, Heinonen PK. Outcome of pregnancies in women with treated or untreated hyperprolactinemia. Eur J Obstet Gynecol Reprod Biol. 1995;63:143–6.CrossRefPubMed
28.
Pearce EN. Thyroid disorders during pregnancy and postpartum. Best Pract Res Clin Obstet Gynaecol. 2015;29:700–6.CrossRefPubMed
29.
Thangaratinam S, Tan A, Knox E, Kilby MD, Franklyn J, Coomarasamy A. Association between thyroid autoantibodies and miscarriage and preterm birth: meta-analysis of evidence. BMJ. 2011;342:d2616.CrossRefPubMedPubMedCentral
30.
Ornoy A, Reece EA, Pavlinkova G, Kappen C, Miller RK. Effect of maternal diabetes on the embryo, fetus, and children: congenital anomalies, genetic and epigenetic changes and developmental outcomes. Birth Defects Res C Embryo Today. 2015;105:53–72.CrossRefPubMed
31.
Hiersch L, Yogev Y. Impact of gestational hyperglycemia on maternal and child health. Curr Opin Clin Nutr Metab Care. 2014;17:255–60.CrossRefPubMed
32.
Czeizel AE, Bánhidy F. Chronic hypertension in pregnancy. Curr Opin Obstet Gynecol. 2011;23:76–81.CrossRefPubMed
33.
Bateman BT, Huybrechts KF, Fischer MA, Seely EW, Ecker JL, Oberg AS, et al. Chronic hypertension in pregnancy and the risk of congenital malformations: a cohort study. Am J Obstet Gynecol. 2015;212:337.e1–e14.CrossRef
34.
Emmanuel Y, Thorne SA. Heart disease in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2015;29:579–97.CrossRefPubMed
35.
Goldrat O, Kroman N, Peccatori FA, Cordoba O, Pistilli B, Lidegaard O, et al. Pregnancy following breast cancer using assisted reproduction and its effect on long-term outcome. Eur J Cancer. 2015;51:1490–6.CrossRefPubMed
36.
Usta IM, Nassar AH. Advanced maternal age. Part I: obstetric complications. Am J Perinatol. 2008;25:521–34.CrossRefPubMed
37.
Nassar AH, Usta IM. Advanced maternal age. Part II: long-term consequences. Am J Perinatol. 2009;26:107–12.CrossRefPubMed
38.
Sauer MV. Reproduction at an advanced maternal age and maternal health. Fertil Steril. 2015;103:1136–43.CrossRefPubMed
39.
Schulkey CE, Regmi SD, Magnan RA, Danzo MT, Luther H, Hutchinson AK, et al. The maternal-age-associated risk of congenital heart disease is modifiable. Nature. 2015;520:230–3.CrossRefPubMedPubMedCentral
40.
41.
Tarín JJ, García-Pérez MA, Hamatani T, Cano A. Infertility etiologies are genetically and clinically linked with other diseases in single meta-diseases. Reprod Biol Endocrinol. 2015;13:31.CrossRefPubMedPubMedCentral
42.
Khalak R, Cummings J, Dexter S. Maternal obesity: significance on the preterm neonate. Int J Obes (Lond). 2015;39:1433–6.
43.
Marchi J, Berg M, Dencker A, Olander EK, Begley C. Risks associated with obesity in pregnancy, for the mother and baby: a systematic review of reviews. Obes Rev. 2015;16:621–38.CrossRefPubMed
44.
Cyganek K, Hebda-Szydlo A, Skupien J, Katra B, Janas I, Borodako A, et al. Glycemic control and pregnancy outcomes in women with type 2 diabetes from Poland. The impact of pregnancy planning and a comparison with type 1 diabetes subjects. Endocrine. 2011;40:243–9.CrossRefPubMed
45.
Gutaj P, Sawicka-Gutaj N, Brazert M, Wender-Ozegowska E. Insulin resistance in pregnancy complicated by type 1 diabetes mellitus. Do we know enough? Ginekol Pol. 2015;86:219–23.CrossRefPubMed
46.
Vinceti M, Malagoli C, Rothman KJ, Rodolfi R, Astolfi G, Calzolari E, et al. Risk of birth defects associated with maternal pregestational diabetes. Eur J Epidemiol. 2014;29:411–8.CrossRefPubMed
47.
Malek A. The impact of metabolic disease associated with metabolic syndrome on human pregnancy. Curr Pharm Biotechnol. 2014;15:3–12.CrossRefPubMed
48.
Kvetny J, Poulsen H. Transient hyperthyroxinemia in newborns from women with autoimmune thyroid disease and raised levels of thyroid peroxidase antibodies. J Matern Fetal Neonatal Med. 2006;19:817–22.CrossRefPubMed
49.
Dallas JS. Autoimmune thyroid disease and pregnancy: relevance for the child. Autoimmunity. 2003;36:339–50.CrossRefPubMed
50.
Svensson J, Lindberg B, Ericsson UB, Olofsson P, Jonsson B, Ivarsson SA. Thyroid autoantibodies in cord blood sera from children and adolescents with autoimmune thyroiditis. Thyroid. 2006;16:79–83.CrossRefPubMed
51.
Wilson RM, Messaoudi I. The impact of maternal obesity during pregnancy on offspring immunity. Mol Cell Endocrinol. 2015;418(Pt 2):134–42.CrossRefPubMed
52.
53.
Armenian SH, Landier W, Francisco L, Herrera C, Mills G, Siyahian A, et al. Long-term pulmonary function in survivors of childhood cancer. J Clin Oncol. 2015;33:1592–600.CrossRefPubMedPubMedCentral
54.
Lapinsky SE, Tram C, Mehta S, Maxwell CV. Restrictive lung disease in pregnancy. Chest. 2014;145:394–8.CrossRefPubMed
55.
McAuliffe F, Kametas N, Rafferty GF, Greenough A, Nicolaides K. Pulmonary diffusing capacity in pregnancy at sea level and at high altitude. Respir Physiol Neurobiol. 2003;134:85–92.CrossRefPubMed
56.
Giussani DA, Niu Y, Herrera EA, Richter HG, Camm EJ, Thakor AS, et al. Heart disease link to fetal hypoxia and oxidative stress. Adv Exp Med Biol. 2014;814:77–87.CrossRefPubMed
57.
Knijnenburg SL, Mulder RL, Schouten-Van Meeteren AY, Bökenkamp A, Blufpand H, van Dulmen-den Broeder E, et al. Early and late renal adverse effects after potentially nephrotoxic treatment for childhood cancer. Cochrane Database Syst Rev. 2013;10:CD008944.PubMed
58.
Porta C, Cosmai L, Gallieni M, Pedrazzoli P, Malberti F. Renal effects of targeted anticancer therapies. Nat Rev Nephrol. 2015;11:354–70.CrossRefPubMed
59.
Gyamlani G, Geraci SA. Kidney disease in pregnancy: (Women’s Health Series). South Med J. 2013;106:519–25.CrossRefPubMed
60.
Wo JY, Viswanathan AN. Impact of radiotherapy on fertility, pregnancy, and neonatal outcomes in female cancer patients. Int J Radiat Oncol Biol Phys. 2009;73:1304–12.CrossRefPubMedPubMedCentral
61.
Wallace WH, Critchley HO, Anderson RA. Optimizing reproductive outcome in children and young people with cancer. J Clin Oncol. 2012;30:3–5.CrossRefPubMed
62.
Teh WT, Stern C, Chander S, Hickey M. The impact of uterine radiation on subsequent fertility and pregnancy outcomes. Biomed Res Int. 2014;2014:482968.CrossRefPubMedPubMedCentral
63.
Wasilewski-Masker K, Kaste SC, Hudson MM, Esiashvili N, Mattano LA, Meacham LR. Bone mineral density deficits in survivors of childhood cancer: long-term follow-up guidelines and review of the literature. Pediatrics. 2008;121:e705–13.CrossRefPubMed
64.
65.
Kovacs CS et al. Calcium metabolism during pregnancy and lactation. In: De Groot LJ, Beck-Peccoz P, Chrousos G, Dungan K, Grossman A, Hershman JM, editors. Endotext [Internet] (MDText.com, Inc.; 2000-: South Dartmouth (MA). 2015. Available from http://​www.​ncbi.​nlm.​nih.​gov/​books/​NBK279173/​). Accessed 10 March 2015.
66.
Done SL. Fetal and neonatal bone health: update on bone growth and manifestations in health and disease. Pediatr Radiol. 2012;42 Suppl 1:S158–76.CrossRefPubMed
Metadata
Title
Obstetric and offspring risks of women’s morbid conditions linked to prior anticancer treatments
Authors
Juan J. Tarín
Miguel A. García-Pérez
Antonio Cano
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Reproductive Biology and Endocrinology / Issue 1/2016
Electronic ISSN: 1477-7827
DOI
https://doi.org/10.1186/s12958-016-0169-6

Other articles of this Issue 1/2016

Reproductive Biology and Endocrinology 1/2016 Go to the issue

Research

Biological sex identification in the endangered dusky gopher frog (Lithobates sevosa): a comparison of body size measurements, secondary sex characteristics, ultrasound imaging, and urinary hormone analysis methods

Research

Aneuploidy analysis in day 7 human blastocysts produced by in vitro fertilization

Letter to Editor

Comment on “Biosimilar FSH preparations- are they identical twins or just siblings?”

Research

Effect of nerve growth factor on sperm quality in asthenozoosprmic men during cryopreservation

Review

Abdominal ectopic pregnancy after in vitro fertilization and single embryo transfer: a case report and systematic review

Research

Effect of embryo morphology and morphometrics on implantation of vitrified day 3 embryos after warming: a retrospective cohort study